Oral trovafloxacin vs oral cefuroxime ± erythromycin in community-acquired pneumonia

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 301-303

  Peterson, J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME AXETIL; ERYTHROMYCIN; TROVAFLOXACIN;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PNEUMONIA; VERTIGO;

EID: 0032707705     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00101     Document Type: Conference Paper

References (13)

1. 1. LA Mandell 1995 Community-acquired pneumonia: etiology, epidemiology, and treatment Chest 108 2 35S 42S 7634924 10.1378/chest.108.2_Supplement.35S 1:STN:280:DyaK2MzmtFKhug%3D%3D Mandell LA. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995; 108 (2 Suppl): 35S–42S
2. 2. TJ Marrie MJ Fine CM Coley 1996 Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course Am J Med 101 508 15 8948274 10.1016/S0002-9343(96)00255-0 1:STN:280:DyaK2s7gsVWjug%3D%3D Marrie TJ, Fine MJ, Coley CM. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15
3. 3. O Leroy C Santrè C Beuscart 1995 A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit Intensive Care Med 21 25 31 10.1007/BF02425150 Leroy O, Santrè C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21: 25–31
4. 4. J Pachon M Prados F Capote 1990 Severe community-acquired pneumonia Etiology, prognosis, and treatment. Am Rev Respir Dis 142 369 73 1:STN:280:DyaK3czktlWnug%3D%3D Pachon J, Prados M, Capote F, et al. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990; 142: 369–73
5. 5. G Gordon D Throop L Berberian 1996 Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients [abstract] Chest 110 55S 10.1378/chest.110.4_Supplement.55S Gordon G, Throop D, Berberian L, et al. Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients [abstract]. Chest 1996; 110 Suppl.: 55S
6. 6. TM Coque KV Singh BE Murray 1996 Comparative in-vitro activity of the new fluoroquinolones trovafloxacin (CP-99,219) against gram-positive cocci J Antimicrob Chemother 37 1011 6 8737152 10.1093/jac/37.5.1011 1:CAS:528:DyaK28XjvVWqs78%3D Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolones trovafloxacin (CP-99,219) against gram-positive cocci. J Antimicrob Chemother 1996; 37: 1011–6
7. 7. J Child J Andrews F Boswell 1995 The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents J Antimicrob Chemother 35 869 76 7559198 10.1093/jac/35.6.869 1:CAS:528:DyaK2MXmslKls7o%3D Child J, Andrews J, Boswell F, et al. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869–76
8. 8. D Felmingham MJ Robbins K Ingley 1997 In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates J Antimicrob Chemother 39 43 9 9222069 10.1093/jac/39.suppl_2.43 1:CAS:528:DyaK2sXksFWqt78%3D Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997; 39 Suppl. B: 43–9
9. 9. PH Edelstein MAC Edelstein J Ren 1996 Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia Antimicrob Agents Chemother 40 314 9 8834872 1:CAS:528:DyaK28Xos1WmsA%3D%3D Edelstein PH, Edelstein MAC, Ren J, et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40: 314–9
10. 10. PM Roblin A Kutlin MR Hammerschlag 1997 In vitro activity of trovafloxacin against Chlamydia pneumoniae Antimicrob Agents Chemother 41 2033 4 9303410 1:CAS:528:DyaK2sXlvFOgu7k%3D Roblin PM, Kutlin A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997; 41: 2033–4
11. 11. JM Andrews D Honeybourne NP Brenwald 1997 Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy J Antimicrob Chemother 39 797 802 9222050 10.1093/jac/39.6.797 1:CAS:528:DyaK2sXksFWqsb4%3D Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: 797–802
12. 12. R Teng TE Liston SC Harris 1996 Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers J Antimicrob Chemother 37 955 63 8737145 10.1093/jac/37.5.955 1:CAS:528:DyaK28XjvVWqsro%3D Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37: 955–63
13. 13. J Vincent R Teng LC Dogolo 1997 Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers J Antimicrob Chemother 39 81 6 9222075 10.1093/jac/39.suppl_2.81 1:CAS:528:DyaK2sXksFWqt7k%3D Vincent J, Teng R, Dogolo LC, et al. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997; 39 Suppl. B: 81–6